MedPath

Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer Surgery

Not Applicable
Recruiting
Conditions
Breast Cancer
Registration Number
NCT04933266
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

The objective of this study is to compare two different doses of local anesthetics (10ml vs 20ml of 0.25% levobupivacaine) for subpectoral plexus block (SPPB) in addition to ultrasound guided multi-level of thoracic paravertebral block (m-TPVB) for surgical anaesthesia for major primary breast cancer surgery.

Detailed Description

Primary breast cancer surgery is one of the most commonly performed surgeries worldwide. It is associated with significant acute postoperative pain and a high incidence of chronic postsurgical pain. Regional anaesthetic techniques are shown to improve outcomes such as postoperative analgesia, nausea, vomiting, delirium and promote early recovery. Currently majority of the breast cancer surgery is performed under general anaesthesia with a multimodal analgesic regimen with or without regional blocks. In fact, it is proved that breast cancer surgery can be done solely under regional anesthesia using multilevel thoracic paravertebral block (TPVB) with deep sedation, but rescue analgesia are often required intraoperatively, especially when surgeons handles the pectoralis muscle. Current evidence suggest that pectoral nerves, which are often described as a pure motor nerves that control movements only, also able to send noxious stimulation such as pain from the pectoral muscles and its deep fascia (via afferent nociceptive fibers) to the brain. Principal investigator proposes that adding a subpectoral plexus block (SPPB) will stop a wider spectrum of afferent nociceptive fibers from sending any pain signals than having thoracic paravertebral block alone. However, there is no report on the amount of local anaesthetic (LA) required to achieve surgical anaesthesia for breast surgery. The aim of this study is to evaluate the effectiveness of two different doses (10ml vs 20ml of 0.25% levobupivacaine) of local anaesthetic (LA) for subpectoral plexus in addition to 3 levels of TPVB injections at T2, T4, and T6 under ultrasound guidance for surgical anaesthesia for major breast cancer surgery.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • scheduled for mastectomy, modified radical mastectomy or breast conservative surgery with lymph node biopsy and with or without axillary dissection
Exclusion Criteria
  • local skin site infection
  • coagulopathy
  • history of allergy to local anesthetics

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Proportion of patients requiring intraoperative ketamineduring surgery

The total number of patients (in percentage) requiring intraoperative ketamine bolus during the surgery

Secondary Outcome Measures
NameTimeMethod
Total amount of rescue ketamine usedduring surgery

The total amount of rescue ketamine (mg) required during surgery

Pain score at Discharge of Post Anaesthetic Care Unit (PACU)immediately before discharge from PACU

Pain Score (Numeric rating scale 0-100; 0=no pain, 100=severe pain) at discharge from PACU

Specific surgical region requiring rescue ketamineduring surgery

The exact surgical region(s), such as infraclavicular, parasternal, axillary, subcostal) that rescue ketamine has to be given during surgery

Pain score on admission at Post Anaesthetic Care Unit (PACU)Assessed once on admission at Post Anaesthetic Care Unit immediately after surgery

Pain score (Numeric rating scale 0-100; 0=no pain, 100=severe pain) on admission at PACU

Trial Locations

Locations (1)

North District Hospital

🇭🇰

Sheung Shui, New Territories, Hong Kong

North District Hospital
🇭🇰Sheung Shui, New Territories, Hong Kong
Hoi Ling Wong, RN, BN, MSc
Contact
+852 55696157
cheukmancheung@cuhk.edu.hk
Manoj K Karmakar, MD
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.